Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

EGFR EGFR

EGFR EGFR RESEARCH ARTICLE EGFR Promoter Methylation, EGFR Mutation, and HPV Infection in Chinese Cervical Squamous Cell Carcinoma Wei Zhang, MD,*w Yinghao Jiang, MSc,* Qingmiao Yu, MSc,z Shaoying Qiang, MSc,y Ping Liang, MSc,* Yane Gao, MD,z Xingye Zhao, BSc,* Wenchao Liu, MD,y and Ju Zhang, PhD* standing and an applicable pharmacogenomic tool for in- Abstract: Therapy strategy toward epidermal growth factor re- dividualized management of cervical cancer patients. ceptor (EGFR) inhibition in cervical cancer has been ongoing. Key Words: epidermal growth factor receptor (EGFR), methyl- EGFR promoter methylation status and EGFR tyrosine kinase ation, mutation, human papillomavirus (HPV), cervical squ- inhibitor–sensitive mutations in cervical cancer may be sig- amous cell carcinoma nificant for clinical outcome prediction using anti-EGFR treatment. In this study, EGFR tyrosine kinase inhibitor– (Appl Immunohistochem Mol Morphol 2015;00:000–000) sensitive mutations, EGFR exons 18, 19, and 21 mutations, were detected by sequencing in a total of 293 Chinese cervical squamous cell carcinoma tissue samples. EGFR promoter ervical cancer is the second most common malig- methylation status was detected by an EGFR asymmetric PCR Cnancy in women worldwide. In China, the incidence and hybridization-fluorescence polarization assay and sequenc- of cervical cancer has been increasing and the average age ing in http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

Loading next page...
 
/lp/wolters-kluwer-health/egfr-egfr-WFVhrt5nGr
Copyright
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1541-2016
DOI
10.1097/PAI.0000000000000128
pmid
25789535
Publisher site
See Article on Publisher Site

Abstract

RESEARCH ARTICLE EGFR Promoter Methylation, EGFR Mutation, and HPV Infection in Chinese Cervical Squamous Cell Carcinoma Wei Zhang, MD,*w Yinghao Jiang, MSc,* Qingmiao Yu, MSc,z Shaoying Qiang, MSc,y Ping Liang, MSc,* Yane Gao, MD,z Xingye Zhao, BSc,* Wenchao Liu, MD,y and Ju Zhang, PhD* standing and an applicable pharmacogenomic tool for in- Abstract: Therapy strategy toward epidermal growth factor re- dividualized management of cervical cancer patients. ceptor (EGFR) inhibition in cervical cancer has been ongoing. Key Words: epidermal growth factor receptor (EGFR), methyl- EGFR promoter methylation status and EGFR tyrosine kinase ation, mutation, human papillomavirus (HPV), cervical squ- inhibitor–sensitive mutations in cervical cancer may be sig- amous cell carcinoma nificant for clinical outcome prediction using anti-EGFR treatment. In this study, EGFR tyrosine kinase inhibitor– (Appl Immunohistochem Mol Morphol 2015;00:000–000) sensitive mutations, EGFR exons 18, 19, and 21 mutations, were detected by sequencing in a total of 293 Chinese cervical squamous cell carcinoma tissue samples. EGFR promoter ervical cancer is the second most common malig- methylation status was detected by an EGFR asymmetric PCR Cnancy in women worldwide. In China, the incidence and hybridization-fluorescence polarization assay and sequenc- of cervical cancer has been increasing and the average age ing in

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: Mar 1, 2015

There are no references for this article.